|1.||Rahman, Mahboob U: 23 articles (01/2014 - 03/2007)|
|2.||Hsia, Elizabeth C: 22 articles (03/2015 - 04/2008)|
|3.||Mack, Michael: 17 articles (03/2015 - 11/2008)|
|4.||van der Heijde, Désirée: 15 articles (04/2015 - 09/2010)|
|5.||Xu, Zhenhua: 15 articles (12/2014 - 03/2007)|
|6.||Xu, Stephen: 14 articles (04/2015 - 06/2010)|
|7.||Hsu, Benjamin: 13 articles (04/2015 - 11/2008)|
|8.||Beutler, Anna: 12 articles (09/2014 - 11/2008)|
|9.||Braun, Jürgen: 11 articles (04/2015 - 11/2008)|
|10.||Matteson, Eric L: 11 articles (01/2015 - 04/2008)|
07/01/2013 - "The objective of this study is to evaluate the efficacy of golimumab (GLM) in Japanese patients with active rheumatoid arthritis (RA) for 1 year. "
02/01/2013 - "This approach was applied to data from two phase III clinical trials of intravenously administered golimumab for the treatment of rheumatoid arthritis, where 20, 50, and 70% improvement in the American College of Rheumatology disease severity criteria were used as efficacy endpoints. "
01/01/2015 - "Predictive factors related to the efficacy of golimumab in patients with rheumatoid arthritis."
03/01/2013 - "Evaluate the efficacy of intravenous golimumab 2 mg/kg+methotrexate (MTX) in patients with active rheumatoid arthritis (RA) receiving MTX. "
01/01/2016 - "The aim of this study was to determine whether the levels of stromal cell-derived factor (SDF)-1 and its receptor C-X-C chemokine receptor 4 (CXCR4) in synovium were correlated with clinical outcome and bone and joint destruction in rheumatoid arthritis (RA) patients being treated with golimumab. "
09/01/2013 - "Golimumab, a human anti-TNF antibody, is effective in patients with ulcerative colitis, according to new findings from an international phase III double-blind trial. "
07/01/2014 - "Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab."
01/01/2014 - "Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg golimumab had clinical remission and mucosal healing at weeks 30 and 54. "
01/01/2014 - "Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis."
07/01/2013 - "IBD: Golimumab shows promise in treatment of active ulcerative colitis."
01/01/2009 - "In patients with psoriatic arthritis in the GO-REVEAL study, significantly more golimumab than placebo recipients achieved a >or=20% improvement in ACR criteria at week 14. "
08/01/2012 - "Golimumab, administered subcutaneously every 4 weeks, has been shown to be effective in reducing the signs and symptoms of active psoriatic arthritis (PsA) through week 24 of the GO-REVEAL study. "
01/01/2013 - "Clinical trials have demonstrated the efficacy of golimumab (GLB) in improving the signs and symptoms of psoriatic arthritis (PsA). "
09/01/2014 - "Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)."
05/01/2014 - "Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab."
01/01/2009 - "Golimumab was also superior to placebo for improving the signs and symptoms of ankylosing spondylitis in the GO-RAISE study; significantly more golimumab than placebo recipients achieved a >or=20% improvement in the Assessment in Ankylosing Spondylitis (ASAS) criteria at week 14. "
09/01/2014 - "Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial."
04/01/2015 - "Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study."
06/01/2014 - "The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial."
06/01/2014 - "The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial."
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
08/01/2015 - "Therefore, we administered golimumab 50 mg. The skin lesions improved significantly according to the Psoriasis Area and Severity Index score after the first administration; lesions improved further throughout the treatment course. "
04/01/2009 - "Treatment with golimumab at doses of 50 mg and 100 mg significantly improved active PsA and associated skin and nail psoriasis through week 24."
04/01/2009 - "Among the 74% of patients in whom at least 3% of the body surface area was affected by psoriasis at baseline, 40% of those in the golimumab 50 mg group and 58% of those in the golimumab 100 mg group had at least 75% improvement in the PASI at week 14 (major secondary end point), compared with 3% of placebo-treated patients (P < 0.001 for both doses). "
08/01/2015 - "Erythrodermic Psoriasis Treated with Golimumab: A Case Report."
12/01/2014 - "Intensification therapy with golimumab: a new treatment strategy for moderate-severe refractory psoriasis."
|4.||TNFR-Fc fusion protein (etanercept)
|6.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||monoclonal antibody CNTO 1275 (CNTO 1275)
|4.||Investigational Therapies (Experimental Therapy)